Robert J. Fox

Multiple sclerosis: disease markers accelerate progress.

New directions in MS therapeutics: vehicles of hope.

Brain atrophy and magnetization transfer ratio following methylprednisolone in multiple sclerosis: short-term changes and long-term implications.

Modulating CCR2 and CCL2 at the blood-brain barrier: relevance for multiple sclerosis pathogenesis.

Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients.

Multiple sclerosis: advances in understanding, diagnosing, and treating the underlying disease.

Multiple sclerosis: treating symptoms, and other general medical issues.

Should patients with relapsing multiple sclerosis be given a higher dose and frequency of interferon-beta1a?

Treatment of Susac syndrome with gamma globulin and corticosteroids.

Optimal reference population for the multiple sclerosis functional composite.

Neurogenesis in the chronic lesions of multiple sclerosis.

Multiple sclerosis: chemokine receptor expression on circulating lymphocytes in correlation with radiographic measures of tissue injury.

A preliminary validation study of diffusion tensor imaging as a measure of functional brain injury.

Picturing multiple sclerosis: conventional and diffusion tensor imaging.

Imaging correlates of leukocyte accumulation and CXCR4/CXCL12 in multiple sclerosis.

Diagnosing multiple sclerosis at a later age: more than just progressive myelopathy.

Measuring myelin repair and axonal loss with diffusion tensor imaging.

Web-based self-management for patients with multiple sclerosis: a practical, randomized trial.

Advanced MRI in multiple sclerosis: current status and future challenges.

Demyelination causes synaptic alterations in hippocampi from multiple sclerosis patients.

Chronic cerebrospinal venous insufficiency: a Kuhnian paradigm shift or another fad?

Advances in the management of PML: focus on natalizumab.

A validation study of multicenter diffusion tensor imaging: reliability of fractional anisotropy and diffusivity values.

Risk stratification and patient counseling for natalizumab in multiple sclerosis.

Chronic cerebrospinal venous insufficiency as a cause of multiple sclerosis: controversy and reality.

Setting a research agenda for progressive multiple sclerosis: the International Collaborative on Progressive MS.

A technical approach to dissecting and assessing cadaveric veins pertinent to chronic cerebrospinal venous insufficiency in multiple sclerosis.

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.

Cortical remyelination: a new target for repair therapies in multiple sclerosis.

Clinically feasible MTR is sensitive to cortical demyelination in MS.

High hypothetical interest in physician-assisted death in multiple sclerosis.

In the coming year we should abandon interferons and glatiramer acetate as first-line therapy for MS: yes.

Hippocampal demyelination and memory dysfunction are associated with increased levels of the neuronal microRNA miR-124 and reduced AMPA receptors.

Multiple sclerosis treatment: risk mitigation.

Is neuromyelitis optica with advanced age of onset a paraneoplastic disorder?

BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety.

Hydration status substantially affects chronic cerebrospinal venous insufficiency assessments.

Injury to a specific neural pathway detected by ultra-high-field MRI.

Treatment discontinuation and disease progression with injectable disease-modifying therapies: findings from the north american research committee on multiple sclerosis database.

MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study.

Defining the clinical course of multiple sclerosis: The 2013 revisions.

Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS).

Factors associated with clinically significant increased walking time in multiple sclerosis: results of a survival analysis of short-term follow-up data from a clinical database.

Risk stratification and mitigation multiple sclerosis.

Biomarkers for MS: unpuzzling the progressive multiple sclerosis puzzle.

Effects of delayed-release dimethyl fumarate (DMF) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies.

Identifying the start of multiple sclerosis injury: a serial DTI study.

Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study.

Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials.

Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives.

Observations on the brain vasculature in multiple sclerosis: A historical perspective.

Comment: A better measuring stick for walking in multiple sclerosis.

Progressive multiple sclerosis.

Disability progression in relapsing MS is more than just lesions: The lesson of fingolimod.

Risk tolerance to MS therapies: Survey results from the NARCOMS registry.

Chronic cerebrospinal venous insufficiency: pitfalls and perils of sonographic assessment.

The Future of Research in Multiple Sclerosis.

No Association of Chronic Cerebrospinal Venous Insufficiency with Multiple Sclerosis.

Progressive MS: from pathophysiology to drug discovery.

Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl Fumarate.

Consensus Management of Gastrointestinal Events Associated with Delayed-Release Dimethyl Fumarate: A Delphi Study.

Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies.

Prevalence of multiple sclerosis symptoms across lifespan: data from the NARCOMS Registry.

Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience.

Correlating Function and Imaging Measures of the Medial Longitudinal Fasciculus.

Refining diagnosis of multiple sclerosis with revised MRI criteria.

Reassessing the risk of natalizumab-associated PML.

Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies.

Relationship between symptom change, relapse activity and disability progression in multiple sclerosis.

Erratum to: Reassessing the risk of natalizumab-associated PML.

Relapses in multiple sclerosis: Relationship to disability.

JC Polyomavirus Abundance and Distribution in Progressive Multifocal Leukoencephalopathy (PML) Brain Tissue Implicates Myelin Sheath in Intracerebral Dissemination of Infection.

Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study.

Safety and Tolerability of Delayed-Release Dimethyl Fumarate Administered with Interferon Beta or Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis.

Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS: Patient management considerations.

Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis.

Quantitative quality assurance in a multicenter HARDI clinical trial at 3T.

Measuring Brain Tissue Integrity during 4 Years Using Diffusion Tensor Imaging.

Imaging as an Outcome Measure in Multiple Sclerosis.

Inadequate outcome measures are the biggest impediment to successful clinical trials in progressive MS - NO.

Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis.

Examining the joint effect of disability, health behaviors, and comorbidity on mortality in MS.

Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function.

Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up.

Evidence of activation of the Nrf2 pathway in multiple sclerosis patients treated with delayed-release dimethyl fumarate in the Phase 3 DEFINE and CONFIRM studies.

Landscape of MS patient cohorts and registries: Recommendations for maximizing impact.

Comparative effectiveness of delayed-release dimethyl fumarate versus glatiramer acetate in multiple sclerosis patients: results of a matching-adjusted indirect comparison.

Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis.

Autologous hematopoietic stem cell transplantation for MS: Safer than previously thought.

Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM.

Efficacy and Tolerability of Delayed-release Dimethyl Fumarate in Black, Hispanic, and Asian Patients with Relapsing-Remitting Multiple Sclerosis: Post Hoc Integrated Analysis of DEFINE and CONFIRM.

DNA methylation in demyelinated multiple sclerosis hippocampus.

T1-/T2-weighted ratio differs in demyelinated cortex in multiple sclerosis.

Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up.

Advancing trial design in progressive multiple sclerosis.

Perspectives on marijuana use and effectiveness: A survey of NARCOMS participants.

Treatment satisfaction and bothersome bladder, bowel, sexual symptoms in multiple sclerosis.

Long-term registries: Answering tough questions with big data?

Tissue Markers for Acute Multiple Sclerosis Treatment Response-A Step Toward Personalized Medicine.

Dimethyl fumarate for relapsing MS.

A survey of dietary characteristics in a large population of people with multiple sclerosis.

Corrigendum to 'Effects of Delayed-release Dimethyl Fumarate (DMF) on Health-related Quality of Life in Patients With Relapsing-remitting Multiple Sclerosis: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies: [Clinical Therapeutics 36 (2014) 1958-1971].

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.

Rare side effects of alemtuzumab remind us of the need for postmarketing surveillance.

Patient-Reported Disease-Modifying Therapy Adherence in the Clinic: A Reliable Metric?

Technical Note: Retrospective reduction in systematic differences across scanner changes by accounting for noise floor effects in diffusion tensor imaging.

Prospects of siponimod in secondary progressive multiple sclerosis.

Scan-rescan repeatability and cross-scanner comparability of DTI metrics in healthy subjects in the SPRINT-MS multicenter trial.

Progressive multifocal leukoencephalopathy with extended natalizumab dosing.

Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers.

Cortical neuronal densities and cerebral white matter demyelination in multiple sclerosis: a retrospective study.

Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis.

Therapeutic Advances and Challenges in the Treatment of Progressive Multiple Sclerosis.

Pseudobulbar affect: Prevalence and association with symptoms in multiple sclerosis.

Validation of the SymptoMScreen with performance-based or clinician-assessed outcomes.

A survey of risk tolerance to multiple sclerosis therapies.

Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice.

The association of fatigue and social participation in multiple sclerosis as assessed using two different instruments.

Measures of general and abdominal obesity and disability severity in a large population of people with multiple sclerosis.

Developing a crosswalk between the RAND-12 and the health utilities index for multiple sclerosis.

Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.

The FLUOX-PMS trial: Underestimating the challenge in progressive multiple sclerosis trials.

Demyelinating lesions and progressive MS: Location, location, location.